Johnson & Johnson
NYSE:JNJ

Watchlist Manager
Johnson & Johnson Logo
Johnson & Johnson
NYSE:JNJ
Watchlist
Price: 151.87 USD -0.89% Market Closed
Market Cap: 365.6B USD
Have any thoughts about
Johnson & Johnson?
Write Note

Johnson & Johnson
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Johnson & Johnson
Revenue Peer Comparison

Comparables:
BMY
PFE
MRK
ZTS
LLY

Competitive Revenue Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Johnson & Johnson
NYSE:JNJ
Revenue
$87.7B
CAGR 3-Years
-1%
CAGR 5-Years
1%
CAGR 10-Years
2%
Bristol-Myers Squibb Co
NYSE:BMY
Revenue
$47.4B
CAGR 3-Years
1%
CAGR 5-Years
14%
CAGR 10-Years
11%
Pfizer Inc
NYSE:PFE
Revenue
$60.1B
CAGR 3-Years
-4%
CAGR 5-Years
14%
CAGR 10-Years
2%
Merck & Co Inc
NYSE:MRK
Revenue
$63.2B
CAGR 3-Years
11%
CAGR 5-Years
7%
CAGR 10-Years
4%
Zoetis Inc
NYSE:ZTS
Revenue
$9.2B
CAGR 3-Years
6%
CAGR 5-Years
8%
CAGR 10-Years
7%
Eli Lilly and Co
NYSE:LLY
Revenue
$40.9B
CAGR 3-Years
14%
CAGR 5-Years
13%
CAGR 10-Years
7%

Johnson & Johnson
Revenue Breakdown

Breakdown by Geography
Johnson & Johnson

Total Revenue: 85.2B USD
100%
United States: 46.4B USD
54.5%
Europe: 20.4B USD
24%
Asia-Pacific, Africa: 13.8B USD
16.2%
Western Hemisphere, Excluding U.s: 4.5B USD
5.3%
Show More
Show Less

Breakdown by Segments
Johnson & Johnson

Total Revenue: 85.2B USD
100%
Innovative Medicine: 54.8B USD
64.3%
Medtech: 30.4B USD
35.7%
Stelara: 10.9B USD
12.8%
Darzalex: 9.7B USD
11.4%
General: 5.4B USD
6.3%
Electrophysiology: 4.7B USD
5.5%
Advanced: 4.7B USD
5.5%
Invega Sustenna/Xeplion/Trinza/Trevicta: 4.1B USD
4.8%
Contact Lenses/Other: 3.7B USD
4.3%
Imbruvica: 3.3B USD
3.8%
Tremfya: 3.1B USD
3.7%
Trauma: 3B USD
3.5%
Spine,Sports & Other: 2.9B USD
3.5%
Erleada: 2.4B USD
2.8%
Xarelto: 2.4B USD
2.8%
Simponi/Simponi Aria: 2.2B USD
2.6%
Opsumit: 2B USD
2.3%
Prezista/Prezcobix/Rezolsta/Symtuza: 1.9B USD
2.2%
Remicade: 1.8B USD
2.2%
Uptravi: 1.6B USD
1.9%
Hips: 1.6B USD
1.8%
Other Neuroscience: 1.6B USD
1.8%
Knees: 1.5B USD
1.7%
Surgical: 1.4B USD
1.6%
Abiomed: 1.3B USD
1.5%
Other: 1.3B USD
1.5%
Edurant/Rilpivirine: 1.2B USD
1.4%
Covid-19: 1.1B USD
1.3%
Zytiga/Abiraterone Acetate: 887m USD
1%
Other Oncology: 879m USD
1%
Concerta/Methylphenidate: 783m USD
0.9%
Risperdal Consta: 689m USD
0.8%
Carvykti: 500m USD
0.6%
Other Interventional Solutions: 356m USD
0.4%
Other Infectious Diseases: 297m USD
0.3%
Other Immunology: 11m USD
0%
Show More
Show Less

See Also

What is Johnson & Johnson's Revenue?
Revenue
87.7B USD

Based on the financial report for Sep 29, 2024, Johnson & Johnson's Revenue amounts to 87.7B USD.

What is Johnson & Johnson's Revenue growth rate?
Revenue CAGR 10Y
2%

Over the last year, the Revenue growth was 5%. The average annual Revenue growth rates for Johnson & Johnson have been -1% over the past three years , 1% over the past five years , and 2% over the past ten years .

Back to Top